



Atty. Dkt. No. 054270-0160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nicholas MANOLIOS
Title: T CELL ANTIGEN RECEPTOR PEPTIDES
Appl. No.: 09/202,305
Filing Date: 03/22/1999
Examiner: Anish Gupta
Art Unit: 1654

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

09/09/2005 09:00:00 00000007 03090205

01 1654

100.00 02

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this supplemental information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

FEE

A fee in connection with submission of a supplemental information disclosure statement under 37 CFR §1.97(d) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 28 January 2005

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By S. A. Bent

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 31, 2005 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/202,305
				Filing Date	03/22/1999
				First Named Inventor	Nicholas MANOLIOS
				Group Art Unit	1654
				Examiner Name	Anish Gupta
				Attorney Docket Number	054270-0160

OIPE
 JAN 31 2005
 U.S. PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C1		WO 95/07707 A		CYTEL CORP	3/23/1995		
	C2		WO 94/20127		CYTEL CORP	9/15/1994		
	C3		WO 96/03140 A		CYTEL CORP	2/8/1996		
	C4		EP 0 443 404 A1		THE MEDICAL COLLEGE OF PENNSYLVANIA	8/28/91		
	C5		WO 95/26980		IMMULOGIC PHARMACEUTICAL CORPORATION	10/12/1995		
	C6		WO 95/34312		TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12/21/1995		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C7	SUPPLEMENTAL EUROPEAN SEARCH REPORT EP 97 92 4813	
	C8	Vijay K. KUCHROO et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire", The Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, vol. 153, no. 7, October 1, 1994, pp. 3326-3336.	
	C9	Stephen C. JAMESON et al., "Clone-specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-restricted Cytotoxic T Cells", Journal of Experimental Medicine, Tokyo, Japan, vol. 177, no. 6, June 1, 1993, pp. 1541-1550.	
	C10	K. HOGQUIST et al., "T Cell Receptor Antagonist Peptides Induce Positive Selection", Cell, Cell Press, Cambridge, MA, US, vol. 76, no. 1, January 14, 1994, pp. 17-27.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/202,305
Date Submitted: January 31, 2005		Filing Date	03/22/1999
(use as many sheets as necessary)		First Named Inventor	Nicholas MANOLIOS
		Group Art Unit	1654
		Examiner Name	Anish Gupta
		Attorney Docket Number	054270-0160
Sheet	2	of	2



NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C11	Shuji IKAGAWA et al., "Single Amino Acid Substitutions on a Japanese Cedar Pollen Allergen (Cry j 1)-derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism", Journal of Allergy and Clinical Immunology, Mosby - Yearly Book, Inc. US, vol. 97, no. 1, part 1, January 1996, pp. 53-64.	
	C12	Geoffrey A. COLE et al., "T Cell Recognition of the Immunodominant Sendai virus NP324-332/Kb epitope is focused on the center of the Peptide", Journal of Immunology, Coden: JOIMA3; ISSN: 0022-1767, vol. 155, no. 6, September 15, 1995 pp. 2841-2848.	
	C13	M. OLDSTONE et al., "Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection", Journal of Virology, The American Society for Microbiology, U.S. vol. 69, no. 12, December 1, 1995, pp. 7423-7429.	
	C14	Nathan KARIN et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production", Journal of Experimental Medicine, Tokyo, JP, vol. 180, no. 6, December 1, 1994, pp. 2227-2237.	
	C15	M. Teresa DE MAGISTRIS et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor", Cell, vol. 68, no. 4, February 21, 1992, pp. 625-634.	
	C16	N.S. SHIMIZU et al., "Inhibition of infection of T-cells with human immunodeficiency virus type 1 by dideoxynucleosides conjugated with oligopeptides", Antiviral Chemistry and Chemotherapy (1995) 6(1), pp. 17-24.	
	C17	Bernard MARI et al., "Thrombin and trypsin-induced Ca ²⁺ mobilization in human T cell lines through interaction with different protease-activated receptors", FASEB JOURNAL, CODEN: FAJOEC; ISSN: 0892-6638, vol. 10, no. 2, February 1996, pp. 309-316.	
	C18	Bjorn R. GUNDLACH et al., "Determination of T cell epitomes with random peptide libraries", Journal of Immunological Methods, CODEM: JIMMBG; ISSN: 0022-1759, vol. 192, no. 1-2, June 10, 1996, pp. 149-155.	
	C19	Thomas C. MANNING et al., "A strategy for the synthesis and screening of thiol-modified peptide variants recognized by T cells", Journal of Immunological Methods, CODEN: JIMMBG; ISSN: 0022-1759, vol. 192, no. 1-2, June 10, 1996, pp. 125-132.	
	C20	Irma JOOSTEN et al., "Direct binding of autoimmune diseases related T cell epitopes to purified Lewis rat MHC class II molecules", INTERNATIONAL IMMUNOLOGY, CODEN: INIMEN; ISSN: 0953-8178, vol. 6, no. 5, May 1994, pp. 751-759.	
	C21	Peter G. LIVINGSTON et al., "Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities", JOURNAL OF IMMUNOLOGY, CODEN: JOIMA3; ISSN: 0022-1767, vol. 154, no. 3, February 1, 1995 pp. 1287-1295.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.